ClinicalTrials.gg
RecruitingNCT06825104TAILORED-LTUpdated Mar 13, 2025

Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

An observational study in Atrial Fibrillation, sponsored by Volta Medical. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Volta Medical · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
278
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Planned enrollment
60th of 123
278 · median 250
Started
2025
with 10 others
Observational
124 of 317
25 open now
Primary completion
2027-12
later than 54 of 86 live
Registered
291st of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 60th largest by planned enrollment of the 123 observational ones that give a count, is one of 11 that started in 2025, is one of 124 observational ones, reaches primary completion later than 54 of the 86 other live ones, and was the 291st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

The TAILORED-LT study is conducted as an extension follow-up until 5 years of the initial TAILORED-AF study (NCT04702451), in order to demonstrate the long-term superiority in terms of freedom of atrial fibrillation (AF) of a tailored ablation strategy targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary veins isolation (PVI) over an anatomical ablation strategy targeting PVI alone for the initial ablation procedure of persistent AF.

Read the detailed description

The TAILORED-AF study demonstrated at one year's follow-up that a tailored ablation strategy guided by Volta Medical AI-software targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary vein isolation (PVI) ablation is more effective to an anatomical ablation strategy targeting PVI alone (current standard of care) for the treatment of persistent atrial fibrillation (AF).

VX1 legacy device renamed Volta AF-Xplorer was used in the TAILORED-AF study in the treatment arm.

No additional treatments are specifically required in the scope of this ancillary TAILORED-LT study which aims to follow the patients previously treated in the initial TAILORED-AF study over the long-term. However, in the event of repeat procedures during the TAILORED-LT study, the choice of the ablation technique will be left to the investigator's discretion, regardless of the patient's randomization arm in the TAILORED-AF study.

The annual follow-up will be performed as in routine clinical practice post AF ablation procedures: visits at 24 months, 36 months, 48 months and 60 months post TAILORED-AF Study index procedure. It is possible that some of these annual visits cannot be completed prospectively due to time already having elapsed between the end of the subject participation in the TAILORED-AF study and the date of enrollment in the extension TAILORED-LT study. In this case, available data (among those expected by the study protocol) will be collected retrospectively.

The additional procedures related to this clinical investigation are limited to annual 24-hour Holters and to the administration of Quality Of Life questionnaires (SF-36 and AFEQT) to the patients during follow-up visits.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Artificial Intelligence
  • VX1
  • Volta AF-Xplorer
  • Medical Device
  • Cardiac Dispersion
  • Volta Medical
  • Software
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients previously enrolled in TAILORED-AF study, treated for their persistent AF by an index ablation procedure and not withdrawn during the 12-month follow-up period post-index procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who participated in the Tailored AF study
  • Patient not withdrawn during the 12-month follow-up period post-index procedure in the Tailored AF study
  • Patient able and willing to provide written to participate in this extension Tailored-LT study

Exclusion criteria

Exclusion Criteria:

  • Person deprived of liberty or under guardianship
  • Person unable to undergo a medical monitoring for geographical, social or psychological reasons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
278 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental: Tailored

    Patients from the "Tailored" group in the initial study TAILORED-AF. Patients in this group underwent "Tailored" AF ablation, i.e. the analysis and targeting of pathological areas using Volta Medical's artificial intelligence software (Volta AF-Xplorer, formerly VX1), in addition to electrical isolation of the pulmonary veins (PVI).

    Device: Volta AF-Xplorer · Procedure: Dispersion ablation + PVI

  • Active Comparator: Anatomical

    Patients from the "Anatomical" group in the initial study TAILORED-AF. Patients in this group underwent PVI only.

    Procedure: PVI

Interventions

  • DeviceVolta AF-Xplorer

    Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms

  • ProcedureDispersion ablation + PVI

    TAILORED-AF index procedure: Dispersion ablation + PVI

  • ProcedurePVI

    TAILORED-AF index procedure: PVI only

06

What researchers measure

Primary outcomes

  1. Long-term freedom from documented atrial fibrillation (AF) after one ablation procedure

    Long-term freedom from documented AF episodes \> 30 seconds, with or without antiarrhythmic drugs (AADs), after a single index ablation procedure.

    Time frame: 60 months

Secondary outcomes

  1. Long-term freedom from documented AF/AT after one or two ablation procedures

    Long-term freedom from documented AF and Atrial Tachycardia (AT) episodes \> 30 seconds, after one or two procedures, with or without AADs

    Time frame: 60 months

  2. Long-term freedom from documented AF/AT after one ablation procedure

    Long-term freedom from documented AF/AT episodes \> 30 seconds, after one procedure, with or without AADs

    Time frame: 60 months

  3. Heath Economics - Average Number of Ablation Procedures per patient

    To determine how the number of repeat ablation procedures in addition to the index procedure impacts health care costs.

    Time frame: 60 months

  4. Heath Economics - Average Number of Hospitalizations per patient

    To determine how the number of hospitalizations post-ablation index procedure impacts health care costs.

    Time frame: 60 months

  5. Heath Economics - Average Number of Cardioversions per patient

    To determine how the number of cardioversions post-ablation index procedure affects health care costs.

    Time frame: 60 months

  6. Heath Economics - Quality of Life Progression (AFEQT Score)

    To determine how the quality of life progression after the ablation index procedure (measured with the Atrial Fibrillation Effect on Quality of Life Questionnaire AFEQT) impacts health care costs. AFEQT score ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: 60 months

  7. Heath Economics - Quality of Life Progression (SF-36 Score)

    To determine how the Quality of life progression after the ablation index procedure (measured with the 36-Item Short Form Health Survey SF-36) impacts health care costs. The SF-36 consists of eight domains measuring physical and mental health, with scores ranging from 0 to 100 (higher scores indicate better quality of life).

    Time frame: 60 months

  8. Heath Economics - Proportion of Patients Under AAD

    To determine how the proportion of patients under antiarrhythmic drugs (AAD) impacts health care costs.

    Time frame: 60 months

  9. Incidence of complications (safety composite endpoint)

    Incidence of complications: death, cerebrovascular events, or serious treatment-related adverse event at long-term. NOTE: In addition, each component of the composite endpoint will be individually assessed.

    Time frame: 60 months

07

Study locations

1 of 13 sites recruiting
  • CHU Lyon, Hôpital Louis Pradel
    Bron, 69677, France
    Not yet recruiting
    • Francis Bessière, MD · Contact
  • Pôle Santé République
    Clermont-Ferrand, 63050, France
    Not yet recruiting
    • Antoine Roux, MD · Contact
  • Hôpital Saint Philibert
    Lomme, 59462, France
    Not yet recruiting
    • Yves Guyomar, MD · Contact
  • Hôpital Saint-Joseph Marseille
    Marseille, 13008, France
    Recruiting
    • Edouard Gitenay, MD · Contact
  • Hôpital Privé Jacques Cartier
    Massy, 91300, France
    Not yet recruiting
    • Jérôme Horvilleur, MD · Contact
  • Hôpital Privé du Confluent
    Nantes, 44277, France
    Not yet recruiting
    • Sélim Abbey, MD · Contact
  • Polyclinique Saint George
    Nice, 06105, France
    Not yet recruiting
    • Guillaume Théodore, MD · Contact
  • Centre Cardiologique du Nord
    Saint-Denis, 93207, France
    Not yet recruiting
    • Antoine Lepillier, MD · Contact
  • Clinique Rhéna
    Strasbourg, 67000, France
    Not yet recruiting
    • Babé Bakouboula, MD · Contact
  • Clinique Pasteur
    Toulouse, 31076, France
    Not yet recruiting
    • Jean-Paul Albenque, MD · Contact
  • CHRU Nancy, Institut Lorrain du coeur et des vaisseaux
    Vandœuvre-lès-Nancy, 54500, France
    Not yet recruiting
    • Christian De Chillou, MD · Contact
  • Klinikum Coburg
    Coburg, 96450, Germany
    Not yet recruiting
    • Mathias Forkmann, MD · Contact
  • German Heart Center
    Munich, 80636, Germany
    Not yet recruiting
    • Isabel Deisenhofer, MD · Contact
08

References and documents

Publications

  • Deisenhofer I, Albenque JP, Busch S, Gitenay E, Mountantonakis SE, Roux A, Horvilleur J, Bakouboula B, Oza S, Abbey S, Theodore G, Lepillier A, Guyomar Y, Bessiere F, Jan Smit J, Mohr Durdez T, Milpied P, Appetiti A, Guerrero D, De Potter T, De Chillou C, Goldbarg S, Verma A, Hummel JD; TAILORED-AF Investigators. Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial. Nat Med. 2025 Apr;31(4):1286-1293. doi: 10.1038/s41591-025-03517-w. Epub 2025 Feb 14. PubMed 39953289 ↗
  • Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065. PubMed 28104073 ↗
  • Seitz J, Durdez TM, Albenque JP, Pisapia A, Gitenay E, Durand C, Monteau J, Moubarak G, Theodore G, Lepillier A, Zhao A, Bremondy M, Maluski A, Cauchemez B, Combes S, Guyomar Y, Heuls S, Thomas O, Penaranda G, Siame S, Appetiti A, Milpied P, Bars C, Kalifa J. Artificial intelligence software standardizes electrogram-based ablation outcome for persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2022 Nov;33(11):2250-2260. doi: 10.1111/jce.15657. Epub 2022 Sep 18. PubMed 35989543 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 33 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 13, 2025
StartActual
Mar 6, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06825104
Lead sponsor
Volta Medical
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Mar 6, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 13, 2025

Study contacts

Paola MILPIED
Contact
paola.milpied@volta-medical.com
(0)768025499 ext. 0033
Cecile BIELMANN
Contact
cecile.bielmann@volta-medical.com
Isabel DEISENHOFER, MD
principal investigator · Deutsches Herzzentrum Muenchen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion